


[doi:10.1016/j.ejca.2009.02.009](https://doi.org/10.1016/j.ejca.2009.02.009)

 Cite or Link Using DOI

Copyright © 2009 Elsevier Ltd All rights reserved.

Editorial Comment

Adjuvant treatment of GIST with imatinib: Solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS)

**Alessandro Gronchi^a, Ian Judson^b, Toshirou Nishida^c, Andres Poveda^d, Javier
Martin^e, Peter Reichardt^f, Paolo G. Casali^g, Axel Le Cesne^h, Peter Hohenbergerⁱ
and Jean-Yves Blayⁱ **

^aSarcoma Unit, Department of Surgery, Istituto Nazionale Tumori, Via G. Venezian 1, 20133 Milano, Italy

^bThe Institute of Cancer Research, Royal Cancer Hospital, 123 Old Brompton Road, London SW7 3RP, UK

^cDepartment of Surgery, E1, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan

^dMedical Oncology Department, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain

^eSkeletal-Muscle Tumour Committee, Hospital Son Dureta, Palma de Mallorca, Spain

^fHELIOS Klinikum Bad Saarow, Pieskower Straße 33, 15526 Bad Saarow, Germany

^gAdult Sarcoma Medical Treatment Unit, Istituto Nazionale Tumori, Via G. Venezian 1, 20133 Milano, Italy

^hDepartment of Medicine, Institut Gustave Roussy, 94805 Villejuif Cedex, France

ⁱDivision of Surgical Oncology and Thoracic Surgery, Mannheim University Medical Centre, University of Heidelberg, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany

^jDepartment of Medicine, Centre Leon Berard, 28, rue Laennec, 69008 Lyon, France

1. [Introduction](#)
2. [Delay or prevention](#)
3. [Overall survival](#)
4. [Resistance to imatinib](#)
5. [Duration of treatment](#)
6. [Selection of patients](#)

7. [Dose](#)